Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51

Benzinga · 3d ago
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.